INTRODUCTION AND OBJECTIVES:
Patients receiving percutaneous tibial nerve stimulation (PTNS) require routine maintenance sessions for sustained efficacy. Currently, no studies characterize compliance with long-term PTNS maintenance. We sought to evaluate PTNS maintenance therapy dropout rates and identify factors associated with compliance.
METHODS: Our PTNS database was queried for patients from 2014-2017. Demographic and visit data were collected. Maintenance therapy was patient driven and frequency of sessions based on symptomology. Dropout from maintenance was assessed at 3, 6, 9, and 12 months after the completion of 12 initial sessions. Multiple variables were tested for correlation with dropout in patients remaining on maintenance therapy for 1 year versus those who discontinued.
RESULTS: We identified 133 PTNS patients, with 96 patients completing initial PTNS therapy and 69 proceeding on maintenance. At 3, 6, 9, and 12 months, continuation rates were 72.4% (50/69), 53.6% (37/69), 43.5% (30/69), and 30.4% (21/69) (Figure 1 ). The mean days until dropout was 187 (SD[134) . Demographic and clinical variables are listed in Table 1 . Common reasons for maintenance dropout were perceived inefficacy (n[10), time commitment (n[5), insurance issues (n[4), and interest in other therapies (n[4). A multivariate logistic regression model found that perceived symptom improvement (HR[43, p[0.034) and Medicare status (HR[96, p[0.027) were positively associated while employment (HR[0.12, p[0.045) was negatively associated with continuing maintenance therapy for greater than 1 year.
CONCLUSIONS: Overall, 30% of patients continued to receive PTNS maintenance therapy 1 year after initial therapy. Approximately 50% of patients stopped maintenance therapy after 7 months. Possible predictors of continued therapy were perceived symptomatic improvement, insurance and employment status. Inefficacy and time commitment were the most commonly cited reasons for dropout. Future studies are required to understand low compliance in PTNS maintenance therapy. METHODS: All Stage I SNM between 2011-16 for overactive bladder (wet or dry) were retrospectively reviewed for intraoperative stimulation amplitudes during implantation and subsequent surgeries. Cases without amplitudes recorded were also assessed. A Stage I amplitude score was calculated by assigning 1 point for each electrode with an amplitude <2 V producing a motor response and 0 points for an electrode requiring an amplitude !2 V to achieve a response (maximum possible score of 4). Stage II implantation and lead revision rates were analyzed using Fisher's exact and chi-square tests, amplitudes were analyzed using student's t test, and p <0.05 was significant.
RESULTS: A total of 109 surgeries had amplitudes recorded and 141 did not. At Stage I, mean age at was 61 years, mean BMI was 31 kg/m 2 , and 85% of patients were female. Median follow up was 683 days. In surgeries with Stage I amplitudes, Stage II implantation rate was 89%, while those without amplitudes had a Stage II rate of 84% (p[0.2). Lead revision rates differed significantly whether Stage I amplitudes were recorded or not -an 18% revision rate following surgeries with amplitudes reported versus 29% in those without amplitudes recorded (p[0.04). Of surgeries with amplitudes noted, mean electrode amplitude in patients progressing to Stage II was 2.2 V versus 1.9 V in those who did not (p[0.2). Mean Stage I amplitude did not differ between patients who underwent a subsequent lead revision and those who did not (2.4 V and 2.2 V, respectively, p[0.5). There was no association between amplitude score and Stage II implantation (p[0.6) or later revision (p[0.3).
CONCLUSIONS: No associations between Stage I amplitudes and sacral neuromodulation outcomes were observed. However, tracking amplitude during Stage I was associated with nearly a 38% reduction in lead revisions, likely by facilitating better lead placement.
